Widely used:Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$----
P/E Ratio
--
P/B Ratio
--
Industry P/E
--
Debt to Equity
--
ROE
--
ROCE
--
Div. Yield
--
Book Value
--
EPS
--
CFO
$-151.84 Mln
EBITDA
$-186.70 Mln
Net Profit
$-149.28 Mln
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|
|---|---|---|---|---|---|---|---|
|
Jasper Therapeutics Inc (JSPRW)
| -53.44 | -31.75 | -32.74 | -38.96 | -31.52 | -- | -- |
|
BSE Sensex*
| 2.25 | 3.09 | 6.15 | 8.51 | 12.08 | 20.31 | 11.40 |
|
S&P Small-Cap 600#
| -5.82 | -5.34 | -13.73 | -6.30 | 5.30 | 2.98 | 5.53 |
|
2024
|
2023
|
|
|---|---|---|
|
Jasper Therapeutics Inc (JSPRW)
| 160.63 | 166.67 |
|
S&P Small-Cap 600
| 7.01 | 13.89 |
|
BSE Sensex
| 8.10 | 18.74 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
3Y Avg -- 5Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Jasper Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing therapeutics targeting mast and hematopoietic stem cell driven diseases. The company's lead product candidate is briquilimab, a monoclonal antibody designed to... block stem cell factor from binding to and signaling through the CD117 receptor on mast and stem cells. It focuses on the development and commercialization of therapeutic agents for patients with various mast cell driven diseases, including chronic spontaneous urticaria, chronic inducible urticaria, and asthma, as well as conditioning agents for stem cell transplant in patients with sickle cell disease, Fanconi anemia, and severe combined immunodeficiency. Jasper Therapeutics, Inc. is headquartered in Redwood City, California. Read more
President, CEO & Director
Mr. Ronald A. Martell
President, CEO & Director
Mr. Ronald A. Martell
Headquarters
Redwood City, CA
Website
Our rating system has guided millions of investors in the past 20 years.
The share price of Jasper Therapeutics Inc (JSPRW) is $0.10 (NASDAQ) as of 23-Apr-2025 16:00 EDT. Jasper Therapeutics Inc (JSPRW) has given a return of -31.52% in the last 3 years.
Jasper Therapeutics Inc (JSPRW) has a market capitalisation of -- as on 23-Apr-2025. As per Value Research classification, it is a Small Cap company.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Jasper Therapeutics Inc (JSPRW) and enter the required number of quantities and click on buy to purchase the shares of Jasper Therapeutics Inc (JSPRW).
Jasper Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing therapeutics targeting mast and hematopoietic stem cell driven diseases. The company's lead product candidate is briquilimab, a monoclonal antibody designed to block stem cell factor from binding to and signaling through the CD117 receptor on mast and stem cells. It focuses on the development and commercialization of therapeutic agents for patients with various mast cell driven diseases, including chronic spontaneous urticaria, chronic inducible urticaria, and asthma, as well as conditioning agents for stem cell transplant in patients with sickle cell disease, Fanconi anemia, and severe combined immunodeficiency. Jasper Therapeutics, Inc. is headquartered in Redwood City, California.
The CEO & director of Mr. Ronald A. Martell. is Jasper Therapeutics Inc (JSPRW), and CFO & Sr. VP is Mr. Ronald A. Martell.
There is no promoter pledging in Jasper Therapeutics Inc (JSPRW).
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|
| Jasper Therapeutics Inc (JSPRW) | Ratios |
|---|---|
|
Return on equity(%)
|
--
|
|
Operating margin(%)
|
--
|
|
Net Margin(%)
|
--
|
|
Dividend yield(%)
|
--
|
No, TTM profit after tax of Jasper Therapeutics Inc (JSPRW) was $0 Mln.
$-0.01
(
